REGENXBIO
regenxbio.com
As featured in
View 2 jobs
Follow
Overview
News
Technologies
Salaries
Products
People
Growth
Jobs
Financials
Overview
Gene therapy has the potential to address the underlying cause of disease, providing single-dose therapies with long-lasting results. REGENXBIO is focused on developing therapies for diseases that have significant unmet needs. Our management team ...
News
REGENXBIO's Multi-Catalyst Setup Is Hard To Ignore (Rating Upgrade) (NASDAQ:RGNX)
Regenxbio surged on milestone revenue and EPS beat, with a $313M cash runway to 2027. Click here to read my most recent analysis.
Read more
Report
Bank of America Securities Reaffirms Their Buy Rating on RegenXBio (RGNX)
Detailed price information for Regenxbio Inc (RGNX-Q) from The Globe and Mail including charting and trades.
Read more
Report
Regenxbio outlines cash runway into Q4 2027 as RGX-202 targets module 1 BLA filing in Q3 2026 (NASDAQ:RGNX)
REGENXBIO (RGNX) Q2 2026 earnings call recap: RGX-202 BLA filing timeline, RGX-121 FDA accelerated path, AbbVie retina milestones, cash runway.
Read more
Report
Analysts Offer Insights on Healthcare Companies: CareDx (CDNA) and RegenXBio (RGNX)
Detailed price information for Regenxbio Inc (RGNX-Q) from The Globe and Mail including charting and trades.
Read more
Report
REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone
REGENXBIO will receive $100 million from AbbVie for this milestone. "Dosing the first patient in the Phase IIb/III study is a significant milestone in our commitment with AbbVie to bring a one-time gene therapy to patients who continue to face progressive
Read more
Report
Pro access
Upgrade to see all 12 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.
Technologies
Tech DNA
SQL
Oracle
AI/ML
SQL
CI/CD
Git
Oracle
Other
ETL/ELT
Stack modernity
81/100
How modern this stack is, based on technology relevance, AI adoption and the share of legacy tools.
In-demand technologies
SQL
1 job
Required
Oracle
1 job
Required
CI/CD
1 job
Required
Git
1 job
Required
ETL/ELT
1 job
Required
Salary medians are calculated from this company's open jobs and compared with the market.
Industry adoption
SQL
18%
CI/CD
18%
Git
12%
Oracle
3%
ETL/ELT
2%
Share of companies in the same industry that use each technology.
Stack changes
ETL/ELT
Aug 2026
Technologies recently added to or removed from this company's stack - a signal of tech migrations and new initiatives.
NXP Semiconductors
DataArt Poland
Accrete
RELX
SpaceX
Vanguard
Growth
Hiring Momentum
48/100
Stable
Open positions
2
0 opened / 2 closed in 30 days
ATS activity
Every ~2 days
08/31/2026
Hiring Dynamics
+100%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Executive
100% ▲
Jobs
≈ $155k – $294k per year (Estimated) • Remote/Hybrid • Full-Time • 12+ years exp • Bachelor's Degree
SQL
Oracle
DevOps
CI/CD
Git
Analytics
ETL/ELT
Apply
Senior Director, Global Program Development Lead - DMD/Neuromuscular
Verified live · 1 day ago 7 months ago≈ $162k – $308k per year (Estimated) • In office • Full-Time • 8+ years exp • Bachelor's Degree
Apply